The American Journal of Pathology
Volume 178, Issue 4 , Pages 1478-1488 , April 2011

Genome and Transcriptome Profiles of CD133-Positive Colorectal Cancer Cells

  • Timo Gaiser

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Jordi Camps

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Sandra Meinhardt

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Danny Wangsa

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Quang Tri Nguyen

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Sudhir Varma

      Affiliations

    • Bioinformatics and Computational Biosciences Branch, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
  • ,
  • Claudia Dittfeld

      Affiliations

    • Tumor Pathophysiology, OncoRay - National Center for Radiation Research in Oncology, Dresden University of Technology, Germany
  • ,
  • Leoni A. Kunz-Schughart

      Affiliations

    • Tumor Pathophysiology, OncoRay - National Center for Radiation Research in Oncology, Dresden University of Technology, Germany
  • ,
  • Ralf Kemmerling

      Affiliations

    • Institute for Pathology, Paracelsus Medical University, Salzburg, Austria
  • ,
  • Maria R. Becker

      Affiliations

    • Dermatology Branch, and the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Kerstin Heselmeyer-Haddad

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • ,
  • Thomas Ried

      Affiliations

    • Section of Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    • Corresponding Author InformationAddress reprint requests to Thomas Ried, M.D., Section of Cancer Genomics, National Institutes of Health, Building 50, Room 1408, 50 South Drive, Bethesda, MD 20892

,Accepted 23 December 2010.

Title About Type File Size
Supplemental Figure S1

A, B: Control group. From eight FFPE blocks, two needle biopsies of approximately 0.5-cm distance in either the CD133+ or CD133− tumor area were cut and analyzed with aCGH for genetic differences (E). After immunohistochemistry for CD133, (C) the CD133+ and CD133− cells were laser microdissected (D) and analyzed with array comparative genomic hybridization for genetic differences (E).

	Other
0 MB
Supplemental Figure S2

Staining was performed according to a conventional set-up used for primary CRC cells in the literature.25,26

	Other
0 MB
Supplemental Figure S3

The proportion of CD133+/CD133− in HCT-116 cultures was not significantly different to the set-up in Supplemental Figure 2. The staining procedure allowed identifying small changes in the CD133 distribution throughout culturing. In short-term cultures after separation, the populations preserved their CD133 expression profile. At later stages, we observed a redistribution of the CD133+ and CD133− cell populations in the cultured CD133+ fraction. Given are the number of passages (P) and of cumulative population doublings (CPD) after sorting. The culture doubling time for the two fractions was identical.

	Other
0 MB
Supplemental Figure S4

CD133+/CD133− distributions after tumor growth in xenografts derived from injection of either CD133+ or CD133− subpopulation estimated by FACS (A) after HT−29 cell injection and (B) after HCT 116 cell injection.

	Other
0 MB
Supplemental Table S1 	Other
0 MB
Supplemental Table S2 	Other
0 MB
Supplemental Table S3 	Other
0 MB

Please note that add-on components may require plug-in applications.

 Supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute. T.G. is supported by a fellowship within the post doctorate program of the Mildred Scheel Foundation. The work performed by the group of LAKS (Tumor Pathophysiology, OncoRay) was supported by the German Research Foundation (DFG) through a grant (KU 971/7-1). OncoRay is funded by the Bundesministerium fuer Bildung und Forschung in the program “Center for Innovation Competence.”

 Supplemental material for this article can be found http://ajp.amjpathol.org or at doi:10.1016/j.ajpath.2010.12.036.

PII: S0002-9440(11)00026-5

doi: 10.1016/j.ajpath.2010.12.036

The American Journal of Pathology
Volume 178, Issue 4 , Pages 1478-1488 , April 2011